An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast cancer
National Institute for Clinical Excellence
Record ID 32002000348
To provide an update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast cancer. This document replaces the previous NICE guidance on the use of taxanes for breast cancer.
Authors' recommendations: The evidence base on paclitaxel as monotherapy for first-line treatment of advanced breast cancer has not changed from the original report, in which there was no evidence that paclitaxel monotherapy was more effective than control treatments. The evidence for the effectiveness of paclitaxel combined with an anthracycline as first-line treatment for advanced breast cancer has not changed substantially from the original report. Paclitaxel may be more effective yet more toxic than non-taxane therapy. Results of ongoing trials are awaited. The evidence base on both taxanes as second-line therapy for advanced breast cancer has not changed from the original report, which found (non-robust) evidence to support the use of docetaxel in second-line therapy of advanced breast cancer, but did not support the use of paclitaxel in this context.
Authors' methods: Systematic review
Project Status: Completed
URL for project: http://www.nice.org.uk/cat.asp?c=22172
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
- Breast Neoplasms
Organisation Name: National Institute for Clinical Excellence
Contact Address: MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.